Patent ID: 9050367
Filing Date: 2015-06-09
Classification: A61K,A61P,A61Q,C12Y,Y02A,Y10T

Abstract:
1. A pharmaceutical composition comprising at least one botulinum neurotoxin selected from Clostridium botulinum of types A, B, C1, D, E, F and G, wherein the at least one botulinum neurotoxin is free of hemagglutinins and non-toxic non-hemagglutinating proteins; a non-proteinaceous stabilizing agent which retains the biological activity of the neurotoxin in an aqueous solution selected from hyaluronic acid, polyvinylpyrrolidone, and polyethylene glycol; a polyalcohol cryoprotectant; and, optionally, a pH buffer; wherein the composition is free from albumin and gelatin.